BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 18, 2014
 |  BioCentury  |  Finance

Big game hunter

Danish Forward Pharma preps to challenge Biogen Idec in MS

Denmark's Forward Pharma A/S has its sights set on big game, including a massive IPO filing in the U.S. and a potential legal battle with Biogen Idec Inc. It's unclear whether buysiders will view the patent spat as an overhang or an investment opportunity.

Forward Pharma filed last week to raise up to $200 million through the sale of ADSs in its IPO. Leerink Partners is the underwriter.

The company's FP187 is an oral, controlled-release formulation of dimethyl fumarate (DMF) that it believes could have better tolerability than first-generation fumarates or Biogen Idec's MS drug Tecfidera dimethyl fumarate.

In 2012, Forward Pharma told BioCentury it was first setting its sights on psoriasis, and if that succeeded, it then would pursue multiple sclerosis. MS now looks to have leapfrogged psoriasis as the lead indication.

This quarter, Forward plans to submit a Phase III protocol to FDA for FP187 to...

Read the full 738 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >